# DENTSPLY SIRONA Inc.: overview

XRAY · Nasdaq · CIK 818479 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xray.md) · [Financials](/companies/xray/financials.md) · [Filings](/companies/xray/filings.md) · [Insiders](/companies/xray/insiders.md)

Latest reported revenue: [$898.0m](/filings/0000818479-26-000255.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000818479-26-000255).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [951](/filings/0000818479-25-000257.md) | [905 d](/filings/0000818479-26-000075.md) | [879](/filings/0000818479-26-000149.md) | [936](/filings/0000818479-26-000255.md) | [904](/filings/0000818479-25-000257.md) | [961 d](/filings/0000818479-26-000075.md) | [880](/filings/0000818479-26-000149.md) | [898](/filings/0000818479-26-000255.md) |
| Gross margin | % | [52.1%](/filings/0000818479-25-000257.md) | [49.3% d](/filings/0000818479-26-000075.md) | [53.0%](/filings/0000818479-26-000149.md) | [52.4%](/filings/0000818479-26-000255.md) | [48.8%](/filings/0000818479-25-000257.md) | [46.1% d](/filings/0000818479-26-000075.md) | [48.5%](/filings/0000818479-26-000149.md) | [54.9%](/filings/0000818479-26-000255.md) |
| Operating margin | % | [(48.6%)](/filings/0000818479-25-000257.md) | [(56.2%) d](/filings/0000818479-26-000075.md) | [7.2%](/filings/0000818479-26-000149.md) | [(13.7%)](/filings/0000818479-26-000255.md) | [(24.1%)](/filings/0000818479-25-000257.md) | [(14.5%) d](/filings/0000818479-26-000075.md) | [(4.0%)](/filings/0000818479-26-000149.md) | [9.1%](/filings/0000818479-26-000255.md) |
| Net margin | % | [(51.9%)](/filings/0000818479-25-000257.md) | [(47.5%) d](/filings/0000818479-26-000075.md) | [2.3%](/filings/0000818479-26-000149.md) | [(4.8%)](/filings/0000818479-26-000255.md) | [(47.2%)](/filings/0000818479-25-000257.md) | [(15.2%) d](/filings/0000818479-26-000075.md) | [(1.1%)](/filings/0000818479-26-000149.md) | [4.1%](/filings/0000818479-26-000255.md) |
| Diluted EPS | $ per share | [(2.46)](/filings/0000818479-25-000257.md) | not reported | [0.10](/filings/0000818479-26-000149.md) | [(0.22)](/filings/0000818479-26-000255.md) | [(2.14)](/filings/0000818479-25-000257.md) | not reported | [(0.05)](/filings/0000818479-26-000149.md) | [0.18](/filings/0000818479-26-000255.md) |
| Free cash flow | $m | [98.0 d](/filings/0000818479-25-000257.md) | [36.0 d](/filings/0000818479-26-000075.md) | [(12.0)](/filings/0000818479-26-000149.md) | [16.0 d](/filings/0000818479-26-000255.md) | [40.0 d](/filings/0000818479-25-000257.md) | [60.0 d](/filings/0000818479-26-000075.md) | [(12.0)](/filings/0000818479-26-000149.md) | [55.0 d](/filings/0000818479-26-000255.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,231](/filings/0000818479-24-000021.md) | [3,922](/filings/0000818479-25-000035.md) | [3,965](/filings/0000818479-26-000075.md) | [3,793](/filings/0000818479-26-000075.md) | [3,680](/filings/0000818479-26-000075.md) |
| Gross margin | % | [55.5%](/filings/0000818479-24-000021.md) | [54.2%](/filings/0000818479-25-000035.md) | [52.6%](/filings/0000818479-26-000075.md) | [51.6%](/filings/0000818479-26-000075.md) | [50.0%](/filings/0000818479-26-000075.md) |
| Operating margin | % | [14.4%](/filings/0000818479-24-000021.md) | [(23.9%)](/filings/0000818479-25-000035.md) | [(2.1%)](/filings/0000818479-26-000075.md) | [(23.2%)](/filings/0000818479-26-000075.md) | [(11.5%)](/filings/0000818479-26-000075.md) |
| Net margin | % | [9.7%](/filings/0000818479-24-000021.md) | [(24.2%)](/filings/0000818479-25-000035.md) | [(3.3%)](/filings/0000818479-26-000075.md) | [(24.0%)](/filings/0000818479-26-000075.md) | [(16.3%)](/filings/0000818479-26-000075.md) |
| Diluted EPS | $ per share | [1.87](/filings/0000818479-24-000021.md) | [(4.41)](/filings/0000818479-25-000035.md) | [(0.62)](/filings/0000818479-26-000075.md) | [(4.48)](/filings/0000818479-26-000075.md) | [(3.00)](/filings/0000818479-26-000075.md) |
| Free cash flow | $m | [515](/filings/0000818479-24-000021.md) | [368](/filings/0000818479-25-000035.md) | [228](/filings/0000818479-26-000075.md) | [281](/filings/0000818479-26-000075.md) | [104](/filings/0000818479-26-000075.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xray/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $283.4m | 26,711,079 |  | Added +7,459,210 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $134.7m | 12,697,269 |  | Reduced −95,249 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $125.0m | 11,779,851 |  | Added +1,249,105 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $110.2m | 10,458,771 |  | Added +6,493,548 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $98.5m | 9,285,298 |  | Added +2,040,461 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $96.0m | 9,047,628 |  | Added +48,071 |
| [LAZARD ASSET MANAGEMENT LLC](/funds/1207017.md) | 2026-06-30 | $87.7m | 8,269,867 |  | Added +1,554,104 |
| [ARIEL INVESTMENTS, LLC](/funds/936753.md) | 2026-06-30 | $85.2m | 8,026,107 |  | Added +1,639,292 |
| [Southpoint Capital Advisors LP](/funds/1319998.md) | 2026-06-30 | $74.3m | 7,000,000 |  | Reduced −3,000,000 |
| [COOKE & BIELER LP](/funds/24386.md) | 2026-06-30 | $73.5m | 6,927,915 |  | Reduced −873,272 |

## Recent filings

[All 3,031 filings](/companies/xray/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 11:42 ET | [8-K/A](/filings/0000818479-26-000263.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000818479-26-000263 |
| 2026-08-06 | 20:56 ET | [10-Q](/filings/0000818479-26-000255.md) | Quarterly report, period 2026-06-30 | 0000818479-26-000255 |
| 2026-08-06 | 20:14 ET | [8-K](/filings/0000818479-26-000253.md) | 9.01 Financial statements and exhibits | 0000818479-26-000253 |
| 2026-06-11 | 12:32 ET | [8-K](/filings/0000818479-26-000200.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000818479-26-000200 |
| 2026-06-04 | 20:23 ET | [8-K](/filings/0000818479-26-000165.md) | 5.07 Shareholder vote results | 0000818479-26-000165 |
| 2026-05-05 | 20:50 ET | [10-Q](/filings/0000818479-26-000149.md) | Quarterly report, period 2026-03-31 | 0000818479-26-000149 |
| 2026-05-05 | 20:18 ET | [8-K](/filings/0000818479-26-000147.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000818479-26-000147 |
| 2026-04-23 | 20:32 ET | [DEF 14A](/filings/0000818479-26-000125.md) | Proxy statement, period 2026-06-02 | 0000818479-26-000125 |
| 2026-02-26 | 21:54 ET | [10-K](/filings/0000818479-26-000075.md) | Annual report, period 2025-12-31 | 0000818479-26-000075 |
| 2026-02-26 | 21:13 ET | [8-K](/filings/0000818479-26-000072.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000818479-26-000072 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000818479-26-000075.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3d30d03b-3eac-40d3-9702-0e486746d80e)

## About the filer

- CIK: 818479
- Tickers: XRAY
- Exchange: Nasdaq
- SIC code: 3843 Dental Equipment & Supplies
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.